Sarepta Loses Bid to Rehear Regenxbio DNA Patent Case Decision

Sarepta Therapeutics Inc. failed to persuade the Federal Circuit to revisit a ruling that revived a gene-therapy patent dispute with Regenxbio Inc. and renewed focus on when altered DNA qualifies for patent protection.

The US Court of Appeals for the Federal Circuit denied Sarepta’s petition for rehearing by the three-judge panel that issued the February decision and by the court’s full slate of judges in an order issued Wednesday.

The denial leaves intact the panel’s precedential finding that US Patent No. 10,526,617 is eligible for patenting under Section 101 of the US Patent Act and leaves the case set to ...